Senators held a hearing on the Patent Eligibility Restoration Act (PERA), with proponents arguing the bill is essential to restore clarity after Supreme Court rulings that muddied patent eligibility for biotech and other fields. Sen. Thom Tillis and witnesses from industry groups including BIO urged lawmakers to codify what cannot be patented and thus protect investments in R&D. Supporters said PERA would reduce litigation risk and encourage domestic innovation; critics questioned whether legislative fixes are needed. The debate matters for biotech companies whose valuations and pipelines hinge on robust and predictable intellectual‑property protections.